To investigate the relationship between the fatty acid-binding protein 4 (FABP4) and colorectal cancer (CRC).
Using an enzyme-linked immunosorbent assay (ELISA), we measured the expression of FABP4 in plasma of 50 patients who underwent surgery for CRC from October 2017 to May 2018 and 50 healthy controls. The content of the visceral fat area (VFA) as seen with abdominal computed tomography (CT) scanning was measured by ImageJ software. The expression levels of FABP4, E-cadherin, and Snail proteins in CRC and adjacent tissues were determined by immunohistochemistry.
The mean concentration of plasma FABP4 of CRC patients was higher than that of the control group (22.46 vs. 9.82 ng/mL; P<0.05). The concentration of plasma FABP4 was related to the tumor, node, metastatis (TNM) stage and lymph node metastasis and was independent of age, body mass index (BMI), tumor size and location, and the degree of differentiation of CRC. The concentration of plasma FABP4 was positively correlated with high VFA and lipoprotein-a (LPA) (P<0.05); but it was not correlated with total cholesterol (TG), total triglyceride (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), or apolipoprotein AI (Apo-AI). The expression of FABP4 protein in CRC tissues was positively correlated with the degree of CRC differentiation, tumor stage, and lymph node metastasis. The level of FABP4 protein was negatively correlated with E-cadherin protein (r= −0.3292, P=0.0196) and positively correlated with Snail protein (r=0.5856, P<0.0001).
High LPA and VFA were risk factors for increased plasma FABP4 in CRC patients. FABP4 protein was highly expressed in CRC tissues and associated with TNM stage, differentiation, and lymph node metastasis of CRC. The level of FABP4 in CRC tissue was correlated with E-cadherin and Snail expression, suggesting that FABP4 may promote CRC progression related to epithelial-mesenchymal transition (EMT).
探讨脂肪酸结合蛋白 4 (FABP4) 与结直肠癌 (CRC)的关系.
结直肠癌患者血浆 FABP4 浓度明显高于对照组 (22.46 ng/mL vs. 9.82 ng/mL, P<0.05). 血浆 FABP4 浓度与肿瘤、 淋巴结、 转移灶 (TNM) 分期和淋巴结转移有关, 与年龄、 身体质量指数 (BMI)、 肿瘤大小、 部位和结直肠癌分化程度无关. 血浆 FABP4 浓度与高内脏脂肪区 (VFA) 和脂蛋白 a (LPA) 呈正相关 (P<0.05), 与总胆固醇 (TG)、 总甘油三酯 (TC)、 低密度脂蛋白 (LDL)、 高密度脂蛋白 (HDL) 以及载脂蛋白 AI 无相关性. FABP4 蛋白在结直肠癌组织中的表达与大肠癌分化程度、 肿瘤分期和淋巴结转移呈正相关. FABP4 蛋白水平与E钙粘蛋白呈负相关 (r=−0.3292, P=0.0196), 与 SNAIL 蛋白呈正相关 (r=0.5856, P<0.0001).
采用酶联免疫吸附试验 (ELISA) 检测了 2017 年 10 月至 2018 年 5 月 50 例大肠癌手术患者和 50 例健康对照者血浆 FABP4 的表达. 用 ImageJ 软件测量腹部 CT 扫描时 VFA 的含量. 免疫组化法检测结直肠癌及癌旁组织中 FABP4、 E-钙粘蛋白 (E-cadherin) 和 Snail 蛋白的表达水平.
高 LPA 和 VFA 是大肠癌患者血浆 FABP4 升高的危险因素. 大肠癌组织中 FABP4 蛋白高表达与淋巴结转移密切相关. 大肠癌组织中 FABP4 水平与 E-cadherin 和 Snail 表达相关, 说明 FABP4 可能与上皮间充质转化 (EMT) 有关.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Furuhashi M, Saitoh S, Shimamoto K, et al., 2014. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol, 8(S3):23–33. https://doi.org/10.4137/cmc.S17067
Gan L, Liu ZJ, Cao WN, et al., 2015. FABP4 reversed the regulation of leptin on mitochondrial fatty acid oxidation in mice adipocytes. Sci Rep, 5:13588. https://doi.org/10.1038/srep13588
Gao XC, 2013. The Effect and Mechanism of Lysophosphatidic Acid Oil Metastasis and Anti-apoptosis in Colorectal Carcinoma. MS Thesis, Guangzhou Medical University, Guangzhou, China (in Chinese).
Guaita-Esteruelas S, Saavedra-García P, Bosquet A, et al., 2017. Adipose-derived fatty acid-binding proteins plasma concentrations are increased in breast cancer patients. Oncologist, 22(11):1309–1315. https://doi.org/10.1634/theoncologist.2016-0483
Jin JB, Zhang ZY, Zhang S, et al., 2018. Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3β/Snail signaling pathway. Mol Cell Endocrinol, 461:155–164. https://doi.org/10.1016/j.mce.2017.09.005
Kooijman EE, Chupin V, Kruijff BD, et al., 2010. Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Traffic, 4(3):162–174. https://doi.org/10.1034/j.1600-0854.2003.00086.x
Lee H, Song MY, Shin N, et al., 2012. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS ONE, 7(4):e34318. https://doi.org/10.1371/journal.pone.0034318
Li H, Chen YX, Wen JG, et al., 2017. Metastasis-associated in colon cancer 1: a promising biomarker for the metastasis and prognosis of colorectal cancer (Review). Oncol Lett, 14(4):3899–3908. https://doi.org/10.3892/ol.2017.6670
Liesenfeld DB, Grapov D, Fahrmann JF, et al., 2015. Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study. Am J Clin Nutr, 102(2):433–443. https://doi.org/10.3945/ajcn.114.103804
Mathis C, Lascombe I, Monnien F, et al., 2018. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. BMC Cancer, 18:1239. https://doi.org/10.1186/s12885-018-5137-4
Miller KD, Nogueira L, Mariotto AB, et al., 2019. Cancer treatment and survivorship statistics, 2019. CA: A Cancer J Clin, 69(5):363–385. https://doi.org/10.3322/caac.21565
Moriarity A, O’Sullivan J, Kennedy J, et al., 2016. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol, 8(4):276–293. https://doi.org/10.1177/1758834016646734
Nam SY, Kim BC, Han KS, et al., 2010. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol, 8(5):443–450.e2. https://doi.org/10.1016/j.cgh.2010.02.001
Nie J, Zhang J, Wang L, et al., 2017. Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. J Exp Clin Cancer Res, 36:183. https://doi.org/10.1186/s13046-017-0641-y
Nieman KM, Kenny HA, Penicka CV, et al., 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 17(11):1498–1503. https://doi.org/10.1038/nm.2492
Tang ZY, Shen Q, Xie H, et al., 2016. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget, 7(29):46253–46262. https://doi.org/10.18632/oncotarget.10086
Uehara H, Takahashi T, Oha M, et al., 2014. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer, 135(11):2558–2568. https://doi.org/10.1002/ijc.28903
Wan XH, Guo DR, Zhu Q, et al., 2020. MicroRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3. Am J Physiol-Gastrointest Liver Physiol, 319(3):G309–G322. https://doi.org/10.1152/ajpgi.00322.2019
Wang J, 2017. Association Between Serum Lipid, FABP4 and Colorectal Carcinoma. MS Thesis, Nanjing University of Chinese Medicine, Nanjing, China (in Chinese).
Zhang YQ, Zhao XT, Deng LL, et al., 2019. High expression of FABP4 and FABP6 in patients with colorectal cancer. World J Surg Oncol, 17(1):171. https://doi.org/10.1186/s12957-019-1714-5
Zheng M, Jiang YP, Chen W, et al., 2015. Snail and slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget, 6(9):6794–6810. https://doi.org/10.18632/oncotarget.3180
Zhong CQ, Zhang XP, Ma N, et al., 2018. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Med, 7(6):2629–2640. https://doi.org/10.1002/cam4.1511
This work was supported by the Science Foundation of Wuxi Health and Family Planning Commission (No. Z201713 to Min XIA), and the Special Project of Clinical Medicine of Nantong University (No. 2019JQ006 to Yan ZHANG), China.
Yan ZHANG, Wenjia ZHANG, Min XIA, Zhujun XIE, Fangmei AN, Qiang ZHAN, Wenying TIAN, and Tianyue ZHU declare that they have no conflict of interest.
The present study was approved by the Ethics Committee of Wuxi People’s Hospital Affiliated to Nanjing Medical University (Wuxi, China) and with the Helsinki Declaration of 1975, as revised in 2008 (5). All the patients and volunteers provided written informed consent for participation in this study. Additional informed consent was obtained from all patients for which identifying information is included in this article.
About this article
Cite this article
Zhang, Y., Zhang, W., Xia, M. et al. High expression of FABP4 in colorectal cancer and its clinical significance. J. Zhejiang Univ. Sci. B 22, 136–145 (2021). https://doi.org/10.1631/jzus.B2000366
- Fatty acid-binding protein 4 (FABP4)
- Colorectal cancer (CRC)
- Epithelial-mesenchymal transition
- 脂肪酸结合蛋白4 (FABP4)
- 结直肠癌 (CRC)